EN DE
Watch Surgical Science Sweden AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Surgical Science Sweden AB (SUS) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Surgical Science Sweden AB stock SEK 48.83, price SEK 61.65, that is 20.8% below the price, quality 62 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0014428512

SS Surgical Science Sweden AB logo Some data Nov 8, 2026

Surgical Science Sweden AB

SUS · ST
Expensive, in a downtrend

Our calculation puts a fair price 21% below what the stock costs today.

Quality 62/100
Healthy Growth (revenue 5y +56.8 %/yr in SEK)
Low debt
Generates free cash flow
Ranks above peers (9/13)
Revenue last quarter +22% vs. a year ago.
Thin margins · 9.1% net margin (TTM)
Some data
Fair value kr 48.83 · Overvalued
Narrow moat 43/100 · thin data
Watch Surgical Science Sweden AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 324.75 kr 23.92 Fair Value kr 48.83 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range kr 23.92 – kr 324.75 · fair‑value band kr 32.10 – kr 75.47 · the kr 61.65 price screens above the kr 48.83 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Surgical Science Sweden in your weekly email

Every Wednesday you see whether Surgical Science Sweden is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally.

Show moreShow less

The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training; URO Mentor, a virtual reality simulator for endourology training; EndoSim, a realistic scope simulator; FlexVR, a flexible and portable training platform which is designed to teach basic and advanced skills for robotic surgery; and LAP Mentor provides a wide array of laparoscopic training cases.

It also provides LapSim training system comprising LapSim Haptic simulator that provides laparoscopic training; LapSim essence, a portable and ready-to-use VR simulator; and LapSim 360, which provides a high-immersion virtual reality training experience; MentorLearn, an end-to-end educational platform that makes simulation course management; and LapSim ST, a training system that prepares students for the operating room.

In addition, the company offers PELVIC Mentor simulator provides anatomy and pelvic exam training; Perc Mentor suite for image-guided interventions; RobotiX Mentor for practice the motor and cognitive skills for surgeons; Simball Box, which combines with digitally collected metrics into a training tool; Spine Mentor, a training simulator for minimal invasive spine surgery; TEE Express, designed to teach Trans-Esophageal Echocardiography procedure using a TEE probe; TraumaVR, an ultimate mix of manikin and VR simulation; and Ultrasound Mentor for ultrasound training with multiple medical specialties.

Surgical Science AB was founded in 1997 and is based in Gothenburg, Sweden.

Stock analysis

Surgical Science Sweden AB (SUS) currently trades at kr 61.65, while our model-based Fair Value estimate is kr 48.83, 21% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of kr 60.47 per share, and 5 of the 24 models we run sit above the kr 61.65 price.

Bear case: the Asset-Based group reads lowest at kr 15.02, and 19 of the 24 models stay below the price. Data coverage for this calculation is medium.

Scenario range: kr 32.10 (bear) to kr 75.47 (bull), the price of kr 61.65 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Surgical Science Sweden AB reported revenue of 992M SEK in FY2025 versus 367M SEK in FY2021, a compound +28.3%/yr. Reported net income was 66.8M SEK in FY2025, compounding −6.2%/yr from FY2021.

Key figures

Market cap 3.1B SEK (≈ $318M) Small · P/E ratio 33.9 · P/S ratio 3.08 · EPS (TTM) kr 1.82 · Net margin 9.1% · Return on equity 2.1% · Return on assets (EBIT) 2.9% (5-year average) · Operating margin 16.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).

What moves the price

The share trades about 27% below its 52-week high and 158% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −21%, SUS screens richer than that median.

Fair Value models

Bear kr 32.10 Fair Value kr 48.83 Bull kr 75.47
Price kr 61.65 · Downside -20.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 1.56 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF kr 33.43 kr 44.32 kr 77.68 79
Growth DCF kr 32.10 kr 48.83 kr 75.47 77
EPV kr 24.93 kr 26.86 kr 28.50 74
All 24 models by family
DCF Models
FCF DCF kr 33.43 kr 44.32 kr 77.68 79
Owner Earnings kr 34.42 kr 60.43 kr 111.31 73
5Y Revenue Exit kr 33.45 kr 49.91 kr 84.44 71
5Y EBITDA Exit kr 46.98 kr 77.27 kr 136.77 72
5Y P/E Exit kr 34.01 kr 60.79 kr 97.21 69
10Y Revenue Exit kr 32.88 kr 59.33 kr 76.68 67
10Y EBITDA Exit kr 43.12 kr 87.15 kr 165.81 64
10Y P/E Exit kr 34.08 kr 60.50 kr 103.74 62
Earnings-Based
Graham-Dodd kr 8.90 kr 62.10 kr 87.15 63
Lynch FV kr 30.50 kr 43.57 kr 56.64 61
PEG = 1.0 kr 30.50 kr 43.57 kr 56.64 57
EPV kr 24.93 kr 26.86 kr 28.50 74
Multiples
P/E Multiple kr 21.61 kr 28.81 kr 36.01 63
P/S Multiple kr 16.70 kr 22.26 kr 27.83 58
P/B Multiple kr 57.75 kr 77.00 kr 96.26 55
EV/EBIT kr 39.28 kr 48.35 kr 57.43 66
EV/EBITDA kr 51.63 kr 64.82 kr 78.01 67
EV/Revenue kr 31.48 kr 39.81 kr 48.14 54
Asset-Based
NCAV (Graham) kr 9.91 kr 15.02 kr 18.77 54
Growth DCF
Growth DCF kr 32.10 kr 48.83 kr 75.47 77
Rev-Margin DCF kr 35.71 kr 55.34 kr 96.29 70
Economic Profit
Residual Income kr 50.70 kr 52.24 kr 56.32 71
ROIC Compounder kr 24.93 kr 26.86 kr 28.50 72
Growth Earnings
Growth-Adj P/E kr 40.88 kr 58.40 kr 75.92 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 62/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 22
How much profit the company makes from its sales and capital
Quality Growth 35
Are margins and returns getting better?
Cashflow 52
Do the profits arrive as real cash?
Financial strength 89
Debt, balance sheet and risk of trouble
Investment 99
Does it invest with discipline instead of growing at any price?
Low Volatility 45
How calm the share price moves, does not count
Price momentum 67
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 34
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.8%
Start year 2020 (pandemic). Over 10 years: +35.9% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.6%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+29.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+29.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.23.6% vs 24.4%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 11%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+22.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +19.7% a year for the price and +6.2% for the forecasts.
Forecast 2026 (sales)+3.2%
Forecast 2027 (sales)+11.4%
Projected 2028 (sales)+10.2%
Projected 2029 (sales)+9.1%
Projected 2030 (sales)+7.9%

SUS screens overvalued: fair value 21% below the price. Compare with Veeva Systems Inc →

Compare Surgical Science Sweden AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks

Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 62 · Above median
Fair Value upside −20.8% · Above median
Profitability
Return on equity (12 months) 2.1% · Below median
Return on assets 1.4% · Above median
Net margin (12 months) 9.1% · Above median
Operating margin (12 months) 16.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 21.7% · Above median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/E (12 months) 33.9× · Pricier than median
P/B 0.74× · Cheapest 25%
P/S (12 months) 3.08× · Pricier than median
Price / free cash flow (fiscal year) 46.2× · Priciest 25%
EV/EBITDA 13.7× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)6 · sector 5
FUTURE (revenue growth)100 · sector 46
PAST (return on equity)8 · sector 10
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 41

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Veeva Systems Inc VEEV $303.73 $334.10 +10% vs SUS
HealthEquity, Inc HQY $103.63 $113.99 +10% vs SUS
Doximity, Inc DOCS $32.51 $35.76 +10% vs SUS
Inventurus Knowledge Solutions Limited IKS ₹1,657 ₹1,823 +10% vs SUS
Waystar Holding WAY $28.35 $29.10 +3% vs SUS
Hinge Health, Inc HNGE $115.76 $51.25 −56% vs SUS
Pro Medicus Limited PME A$205.49 A$85.12 −59% vs SUS
BrightSpring Health Services, Inc BTSG $67.15 $25.72 −62% vs SUS
XtalPi Holdings 2228 HK$6.13 HK$1.53 −75% vs SUS
Privia Health Group PRVA $24.42 $5.52 −77% vs SUS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Surgical Science Sweden AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Surgical Science Sweden AB Fair Value". https://www.fairvalue-calculator.com/stock/SUS

Frequently asked questions

Is Surgical Science Sweden AB (SUS) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of kr 48.83 versus a price of kr 61.65, about 21% lower (overvalued).
What is the fair value of SUS?
Our model-based fair value for Surgical Science Sweden AB is kr 48.83 (as of Nov 8, 2026), built from audited fundamentals. The current price: kr 61.65.
What is the quality score of SUS?
Surgical Science Sweden AB has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Surgical Science Sweden AB (SUS)?
Our model-based price target is the fair value of kr 48.83 (as of Nov 8, 2026) from 24 valuation models. Cautious scenario kr 32.10, optimistic scenario kr 75.47. It is a calculation from audited fundamentals, not an analyst target.
What is the Surgical Science Sweden AB stock forecast for 2026?
Our models put fair value at kr 48.83, about 21% lower versus a price of kr 61.65 (overvalued). Cautious scenario kr 32.10, optimistic scenario kr 75.47. The calculation is refreshed regularly with new filings.
What is the revenue of Surgical Science Sweden AB (SUS)?
Surgical Science Sweden AB reported trailing-twelve-month revenue of about 1.0B SEK (latest available figure, as of Nov 8, 2026).
What growth is priced into Surgical Science Sweden AB (SUS)?
For today's price to be fair in a discounted-cash-flow model, Surgical Science Sweden AB would have to grow free cash flow by +22.1 % per year for five years (discount rate 10.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +56.8 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of SUS use?
Our models discount Surgical Science Sweden AB at 10.0 %: a base by market capitalisation (small), damped by beta 0.64, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Surgical Science Sweden AB that is +22.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.0 %) and the same formula as our fair value.
How much growth has Surgical Science Sweden AB (SUS) delivered so far?
Over the past 5 years revenue at Surgical Science Sweden AB grew +56.8 % a year. The price currently implies free-cash-flow growth of +22.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Surgical Science Sweden AB (SUS) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Surgical Science Sweden AB (+22.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Surgical Science Sweden AB (SUS)?
The free-cash-flow yield on the price is 2.17 %: that much free cash flow Surgical Science Sweden AB produces per unit of market value. When it exceeds the discount rate of our models (10.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Surgical Science Sweden AB (SUS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Surgical Science Sweden AB it is kr 48.83 per share (as of Nov 8, 2026), against a price of kr 61.65. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Surgical Science Sweden AB stock overvalued or undervalued in 2026?
As of Nov 8, 2026, SUS trades above its calculated fair value: price kr 61.65, fair value kr 48.83, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SUS?
No. The price is what the market pays today (kr 61.65); the fair value is what the company's own numbers justify (kr 48.83). For Surgical Science Sweden AB the two are kr 12.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is Surgical Science Sweden AB worth?
The market values Surgical Science Sweden AB at about 3.1B SEK (market capitalisation, as of Nov 8, 2026). Per share that is kr 61.65; our models calculate a fair value of kr 48.83 per share.
What do the bullish and bearish scenarios say about SUS?
Our models span a range for Surgical Science Sweden AB: cautious scenario kr 32.10, base kr 48.83, optimistic kr 75.47 per share (as of Nov 8, 2026, price kr 61.65). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SUS?
Surgical Science Sweden AB trades at a price-to-earnings ratio of 33.9 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 48.83 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 36.1 (reported for FY2025: 47.1). Median P/E at fiscal year-end, 6 fiscal years (2020 to 2025), reported earnings, FY2025 ex one-offs: 52.5. Other multiples: P/B 0.7, P/S 3.1, EV/EBITDA 13.7.
How solid is the balance sheet of Surgical Science Sweden AB (SUS)?
Balance-sheet figures for Surgical Science Sweden AB (as of Nov 8, 2026): return on equity 2.1%. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is SUS from its 52-week high?
Surgical Science Sweden AB trades at kr 61.65, about 27% below its 52-week high of kr 84.15 and 158% above the low of kr 23.92 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 48.83 is for.
Which stocks are comparable to Surgical Science Sweden AB?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Surgical Science Sweden AB stock attractive at the current price?
The data as of Nov 8, 2026: price kr 61.65, calculated fair value kr 48.83 (−21%), Quality Score 62/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SUS calculated?
We run Surgical Science Sweden AB through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of kr 48.83 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Surgical Science Sweden AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Surgical Science Sweden AB (SUS)?
The closing price on Nov 6, 2026 was kr 61.65. Our model-based fair value is kr 48.83, about 21% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Surgical Science Sweden AB right now?
Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 32.10 to kr 75.47) leaves room in how you read the outcome.

Key figures of Surgical Science Sweden AB

How large is the market capitalisation of Surgical Science Sweden AB (SUS)?
The market capitalisation of Surgical Science Sweden AB is 3.1B SEK (≈ $318M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Surgical Science Sweden AB (SUS)?
The price-to-sales ratio of Surgical Science Sweden AB is 3.08 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Surgical Science Sweden AB (SUS)?
Earnings per share at Surgical Science Sweden AB are kr 1.82 (price ÷ EPS = P/E 33.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Surgical Science Sweden AB (SUS)?
The net margin of Surgical Science Sweden AB is 9.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Surgical Science Sweden AB (SUS)?
The return on equity (ROE) of Surgical Science Sweden AB is 2.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Surgical Science Sweden AB (SUS)?
On an EBIT basis the return on assets of Surgical Science Sweden AB is 2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Surgical Science Sweden AB (SUS)?
The operating margin of Surgical Science Sweden AB is 16.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Surgical Science Sweden AB (SUS)?
Revenue at Surgical Science Sweden AB is growing +21.7% versus a year earlier (3y avg +7.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Surgical Science Sweden AB (SUS)?
Earnings per share at Surgical Science Sweden AB are growing −43.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Surgical Science Sweden AB (SUS) hold?
Surgical Science Sweden AB holds more cash than debt, 615M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Surgical Science Sweden AB in the live analysis

One click puts Surgical Science Sweden AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.